Life Sciences Real Estate and the Biotech Tenant

Introduction

In the same period that nationwide laboratory vacancy climbed to roughly 27%, Alexandria Real Estate Equities signed the largest lease in its 31-year history: a 466,598 square foot, 16-year build-to-suit research hub for a multinational pharmaceutical tenant in San Diego. Those two facts are not a contradiction. They are the whole story of life sciences real estate, a sub-type that is less a single market than a violent split between credit-anchored quality and everything else. The category is the highest-beta corner of healthcare real estate because its tenant base is essentially one cyclical end market, biotechnology, and that end market runs on funding that floods in and dries up. When money is abundant, lab space is scarce and rents soar; when funding reverses, the sector discovers it built too much of a product that is extraordinarily expensive to build and nearly impossible to repurpose. Understanding life sciences means understanding why the buildings are special, why demand is a bet on capital flows, and why a downturn rewards the landlords with the strongest tenants and punishes everyone else.

A laboratory building looks like office from the street and behaves nothing like it inside. Lab space is engineered for high electrical loads, heavy ventilation and air exchange, vibration control, redundant power, and chemical handling, none of which a standard office floor provides. Floor-to-floor heights are taller to accommodate mechanical systems, floors are reinforced for heavy equipment, and the buildings carry far more plumbing, exhaust, and backup power than any office requires. These are not cosmetic differences; they are the reason a lab cannot be thrown up quickly or cheaply and the reason a generic office building cannot simply be relabeled as lab without a costly conversion. That specialization shows up in the cost of building it. Ground-up construction in the top markets of San Diego, San Francisco, and Boston-Cambridge runs roughly $675 to $1,200 per square foot, with another $300 to $650 per square foot of tenant improvements on top. More specialized facilities cost far more.

That cost structure has two consequences that define the sub-type. First, supply cannot flex quickly or cheaply, so development is a multi-year bet placed years before the demand it serves actually arrives. A developer who breaks ground in a hot market delivers into whatever market exists two or three years later, which is precisely how the sector overbuilt into the recent downturn. Second, a vacant lab is closer to a stranded asset than a vacant office, because the specialized buildout that makes it valuable to a biotech tenant makes it expensive to convert to anything else. When demand falls, the landlord cannot simply re-lease to a different industry; the building's value is tied to a single, cyclical demand pool.

The specialization also runs in tiers. A flexible lab-office building can sometimes flex between bench research and offices, but purpose-built facilities like vivariums for live-animal research or gene-therapy manufacturing suites are engineered for one use at costs that can exceed $1,200 to $2,000 per square foot, leaving essentially no alternative use if the tenant leaves. The flip side is that office-to-lab conversions, at roughly $300 per square foot, offer a cheaper path to supply than ground-up construction, which is why conversions surged during the boom, the mirror image of the office-to-residential conversion economics playing out in distressed office. The economics of converting into and out of lab use, in both directions, are a recurring theme in how the sub-type's supply adjusts.

Life sciences real estate

Specialized laboratory and research-and-development buildings designed for biotechnology and pharmaceutical tenants, engineered with high power capacity, ventilation, vibration control, and chemical-handling infrastructure that ordinary office space lacks. Because the buildout is purpose-built for research, the asset's value depends on demand from a single industry rather than the broad tenant base that supports office.

The high cost of construction also explains why total fit-out costs averaged about $846 per square foot across all life sciences property subtypes in 2025, and why tenant improvement allowances rose roughly 38% over three years in major markets. Landlords compete for tenants partly by funding ever-richer buildouts, which raises the capital intensity of the business and lengthens the time to recover an investment. Costs did ease slightly into 2026, with fit-out averaging about $741 per square foot as fuel prices fell and contractors bid more competitively, but the structural point holds: lab real estate ties up far more capital per square foot than office, so a landlord cannot afford long vacancy, and a building delivered into a soft market burns cash while it waits for a tenant. The capital intensity is what turns a demand air pocket into real financial pain.

The demand for lab space is downstream of one thing: the money flowing to biotechnology companies. That money comes from three taps, and lab demand rises and falls with all of them. Venture capital funds early-stage biotech and drives demand for startup and incubator space. Public equity markets, through biotech IPO and follow-on windows, fund the scale-up that takes companies into larger labs. And government research budgets, principally the National Institutes of Health, underwrite the academic and translational research that seeds the entire pipeline of future tenants.

The three taps do not move independently. Venture capital is the most sensitive, surging when interest rates are low and risk appetite is high and retreating fast when either reverses. The public biotech window, the ability to IPO or raise follow-on equity, opens and closes with the broader equity market and with sentiment toward drug-development risk. And government research funding, while more stable, is set by political budget cycles that can swing hard, as the proposed NIH cut showed. Because all three respond to the same macro conditions, lab demand is far more cyclical than the demographic-driven demand in the rest of healthcare real estate. A biotech funding boom pulls all three open at once and lab space becomes desperately scarce; a funding winter shuts them together and absorption collapses.

How the boom became the bust

The pandemic-era boom illustrates the mechanism. Cheap capital and a wave of enthusiasm for biotech sent venture and public funding to records, biotech companies raced to lease and pre-lease space, rents spiked, and developers launched an enormous construction pipeline to chase the demand. The buildings took years to deliver. By the time much of that pipeline came online, rates had risen, the public biotech window had slammed shut, venture funding had pulled back, and the demand that justified the construction had evaporated. The supply arrived for a boom that was already over.

This is what makes the sub-type a leveraged bet. An investor in lab real estate is not really buying a building; they are buying exposure to the biotech funding cycle, with a fixed, illiquid, expensive-to-build asset as the vehicle. In the up cycle the leverage works spectacularly: scarce space, soaring rents, and rising values on assets that cost a fortune to replicate. In the down cycle it works in reverse, because the same capital intensity and single-industry demand that amplified the upside now trap the owner in an expensive, hard-to-repurpose building with no tenant. The past few years have been a textbook demonstration of both halves, and the swing between them is far wider than anything the demographic-driven parts of healthcare real estate experience.

The cycle turned hard. A funding boom drove a record development pipeline, and then demand reversed as biotech funding tightened. The reversal was unusually sharp because supply and demand moved in opposite directions at the same time: new buildings kept delivering from the boom-era pipeline just as tenant demand fell off a cliff, so vacancy did not drift up, it spiked. Nationwide lab vacancy climbed to roughly 27%, with Boston, San Francisco, and San Diego, the three core markets, all running vacancy in the high-20s to around thirty percent and asking rents in the top markets down more than 10% from their 2022 peak. Tenant demand in those top markets fell around 60% from its 2021 peak. The supply that looked prescient in 2021 became an overhang, and JLL has projected that nearly 19 million square feet of lab space could be converted to other uses by 2030, a tacit admission that a meaningful slice of the boom-era pipeline will never lease as lab.

The sector bellwether shows what that does to a landlord's numbers. Alexandria posted a third-quarter net loss of roughly $234.9 million, saw occupancy slip to 90.6% from 94.7% a year earlier, and reported same-property net operating income down 6.0% year over year on a GAAP basis as space lingered on the market and re-leasing slowed. Compounding direct vacancy was a wave of sublease space, as biotech tenants that had over-leased in the boom tried to offload square footage they no longer needed, dumping cheap supply onto an already soft market and pressuring rents further. The pain extended to the Big Three healthcare REITs: Healthpeak's decision to lean into outpatient medical and laboratory space, meant to be defensive, turned cyclical at the worst possible moment as its lab segment absorbed the same oversupply.

There were early signs of a turn entering 2026. Policy clarity in the second half of 2025 lifted sentiment, the reversal of the proposed NIH cuts removed a major overhang, and net absorption turned positive for the first time in seven quarters, with about 555,000 square feet absorbed in the fourth quarter of 2025. But a single positive quarter against a 27% vacancy backdrop is a stabilization signal, not a recovery. Working off that much empty space will take years, the weakest buildings will exit the lab inventory through conversion rather than re-lease, and the gap between the strongest and weakest assets kept widening throughout. A recovery in lab real estate does not look like every building filling back up; it looks like the good buildings leasing while the bad ones are repurposed away, which is a slow and capital-destructive process.

Life sciences real estate is unusually concentrated, and the concentration is not arbitrary. Lab demand clusters around the research universities, teaching hospitals, and venture ecosystems that produce both the science and the companies, which is why Boston-Cambridge, the San Francisco Bay Area, and San Diego account for a disproportionate share of institutional-quality lab space. Talent wants to be near other talent, startups want to be near the academic labs they spin out of, and venture investors want their companies nearby.

The three core clusters

Each cluster has its own character. Boston-Cambridge, anchored by MIT, Harvard, and the dense Kendall Square ecosystem, is the deepest and most prestigious market, the one large pharma most wants a presence in. The San Francisco Bay Area, spanning South San Francisco and the Peninsula near Stanford and UCSF, is the second pole, heavily tied to the venture capital that sits next door in Silicon Valley. San Diego, home to UCSD, Scripps, and a strong genomics base, is the third and the one where Alexandria has concentrated its mega-campus build-out. A handful of emerging markets, from the Research Triangle to suburban Maryland near the NIH, round out the map, but they are a fraction of the big three's scale and the first to be cut when budgets tighten.

That clustering is a strength in a boom and a liability in a bust. In the up cycle, the gravitational pull of a cluster makes its lab space irreplaceable and its rents the highest in the country. In the down cycle, the same concentration means oversupply lands in the same few markets with nowhere to diffuse, which is exactly why all three core markets carry vacancy in the high-20s to around thirty percent simultaneously. A more geographically diffuse property type would have spread the pain across many markets; lab real estate concentrated all of it into the same three, which is why the headline vacancy numbers look so severe. This is also why the way a market's property quality and location tiers interact with the cluster matters so much: a top-tier building in the heart of Cambridge and a commodity building on the cluster's edge are barely the same asset class in a downturn.

The owner base is concentrated among specialists, because operating lab real estate requires expertise in building and managing technical facilities and in underwriting biotech tenant credit that generalist landlords lack. Alexandria Real Estate Equities is the dominant public pure-play, the company that effectively created the institutional lab asset class and still sets its standards through the mega-campus model. On the private side, BioMed Realty, owned by Blackstone, is the largest competitor, alongside newer entrants like IQHQ and the lab segments of diversified healthcare REITs such as Healthpeak and Ventas. The depth of that specialist field is itself a barrier: a buyer cannot casually enter lab real estate the way it might buy a suburban office park.

Underwriting a pre-revenue biotech tenant is unlike underwriting a corporate occupier, because the tenant has no earnings to lean on, only a finite pool of raised capital it spends down month by month. The single most important screen is the tenant's cash runway: how many months it can fund operations, including rent, before it must raise again. Divide cash on hand by the monthly cash burn and the result is the number of months the tenant can keep paying.

A startup with a runway shorter than its remaining lease term is a re-leasing risk the moment the funding window closes, because it will shrink, sublease, or fail before the lease expires. This is why a landlord with a rent roll of venture-funded tenants is effectively long the biotech funding cycle through their runways, while a portfolio anchored by investment-grade pharma, which has no runway problem at all, behaves like a bond.

How lab real estate is valued now

How the asset trades follows directly from the funding cycle. In a boom, lab commands premium rents and tight cap rates because the income looks scarce and growing. In the current environment, cap rates have widened and valuations have fallen, and buyers underwrite the credit of the tenant, the weighted average lease term, and the durability of the cluster far more than headline in-place rent. A long lease to investment-grade pharma is valued almost like a corporate bond; a building full of short-dated startup leases is valued at a steep discount for the re-leasing risk. Development pipelines, which were a source of value in the boom, became a liability in the bust, as half-built or newly delivered speculative space sat unleased and consumed capital. The same building can be a prized asset or a problem depending entirely on who occupies it and on what terms.

For a banker, that dispersion is exactly where the opportunity sits. A dislocated sector with a wide gap between strong and weak assets is fertile ground for transactions: distressed sales of over-leveraged speculative buildings, recapitalizations of stalled development, take-privates of public owners trading below the value of their best campuses, and joint ventures that pair a specialist operator's expertise with an institutional investor's capital. The same volatility that punishes passive owners creates a deal pipeline for advisors who can underwrite which assets sit on the right side of the bifurcation. Valuing a lab portfolio in this environment is less about applying a market cap rate and more about sorting the rent roll tenant by tenant into durable credit and re-leasing risk.

The defining feature of this downturn is bifurcation, and Alexandria's strategy is the clearest illustration of which side wins. Even as the broad market sagged, the mega-campus model kept attracting the strongest tenants, because the buildings leasing well were not generic lab boxes. They were amenitized, clustered, large-format campuses anchored by tenants who pay their rent through any funding cycle.

The logic is straightforward once the funding cycle is understood. Large-cap pharmaceutical companies and well-capitalized public biotechs do not stop paying rent when the venture market freezes, so a portfolio anchored by that credit weathers a funding winter. A portfolio full of pre-revenue startups burning venture cash does not: when funding stops, those tenants shrink, sublease their space, or fail, and the landlord is left holding empty specialized buildings in an oversupplied market. Tenant credit and campus quality, not the lab sub-type in the abstract, separate the winners from the losers.

Build-to-suit lease

A lease in which the landlord constructs (or extensively customizes) a building to a specific tenant's requirements in exchange for a long-term commitment, common for large pharma research hubs. Because the tenant is locked in for a long term and the building is purpose-built for its program, a build-to-suit to an investment-grade tenant produces some of the most durable, bond-like income in life sciences real estate.

This is also why life sciences leases reward careful reading. They are typically structured as net leases, often build-to-suit for a specific tenant's research program, so the underlying lease structure and tenant credit drive value as much as the headline rent. A long lease to investment-grade pharma is a different asset from a short lease to a venture-funded startup, even in the same building.

The paradox that defines the asset class is that a 27% vacancy rate and a record-setting lease can be true at the same moment: commodity lab leased to venture-funded startups empties out while credit-anchored mega-campuses leased to large pharma keep signing. That split is the entire investment case. A lab building is a leveraged claim on biotech funding, with specialized infrastructure that cannot easily repurpose and tenants clustered in three cities, so the analyst is really tracking venture flows, NIH policy, and the credit of the rent roll rather than square footage. It is also where real estate runs up against the boundary with healthcare and biotech coverage, the discipline that analyzes the tenants themselves. The building is almost incidental; the tenant credit and the funding cycle are very nearly everything, and an owner who forgets that rides the science economy up with speculative space and fragile tenants straight into the next vacancy spike. The owners who endure are the ones who underwrote the rent roll tenant by tenant, separating durable pharma credit from venture-funded fragility, well before the funding cycle turned against them.